190 related articles for article (PubMed ID: 36102623)
1. Pathogenic variants of sphingomyelin synthase SMS2 disrupt lipid landscapes in the secretory pathway.
Sokoya T; Parolek J; Foged MM; Danylchuk DI; Bozan M; Sarkar B; Hilderink A; Philippi M; Botto LD; Terhal PA; Mäkitie O; Piehler J; Kim Y; Burd CG; Klymchenko AS; Maeda K; Holthuis JCM
Elife; 2022 Sep; 11():. PubMed ID: 36102623
[TBL] [Abstract][Full Text] [Related]
2. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.
Liu J; Zhang H; Li Z; Hailemariam TK; Chakraborty M; Jiang K; Qiu D; Bui HH; Peake DA; Kuo MS; Wadgaonkar R; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):850-6. PubMed ID: 19286635
[TBL] [Abstract][Full Text] [Related]
3. Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
Xue J; Yu Y; Zhang X; Zhang C; Zhao Y; Liu B; Zhang L; Wang L; Chen R; Gao X; Jiao P; Song G; Jiang XC; Qin S
J Am Heart Assoc; 2019 Nov; 8(22):e012885. PubMed ID: 31718447
[TBL] [Abstract][Full Text] [Related]
4. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
[TBL] [Abstract][Full Text] [Related]
6. Imaging Mass Spectrometry Reveals Acyl-Chain- and Region-Specific Sphingolipid Metabolism in the Kidneys of Sphingomyelin Synthase 2-Deficient Mice.
Sugimoto M; Wakabayashi M; Shimizu Y; Yoshioka T; Higashino K; Numata Y; Okuda T; Zhao S; Sakai S; Igarashi Y; Kuge Y
PLoS One; 2016; 11(3):e0152191. PubMed ID: 27010944
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
[TBL] [Abstract][Full Text] [Related]
8. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.
Mitsutake S; Zama K; Yokota H; Yoshida T; Tanaka M; Mitsui M; Ikawa M; Okabe M; Tanaka Y; Yamashita T; Takemoto H; Okazaki T; Watanabe K; Igarashi Y
J Biol Chem; 2011 Aug; 286(32):28544-55. PubMed ID: 21669879
[TBL] [Abstract][Full Text] [Related]
9.
Pihlström S; Richardt S; Määttä K; Pekkinen M; Olkkonen VM; Mäkitie O; Mäkitie RE
Front Endocrinol (Lausanne); 2023; 14():1224318. PubMed ID: 37886644
[TBL] [Abstract][Full Text] [Related]
10. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
[TBL] [Abstract][Full Text] [Related]
11. Sphingomyelin synthase 2, but not sphingomyelin synthase 1, is involved in HIV-1 envelope-mediated membrane fusion.
Hayashi Y; Nemoto-Sasaki Y; Tanikawa T; Oka S; Tsuchiya K; Zama K; Mitsutake S; Sugiura T; Yamashita A
J Biol Chem; 2014 Oct; 289(44):30842-30856. PubMed ID: 25231990
[TBL] [Abstract][Full Text] [Related]
12. [Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice].
Qin R; Chen ML; Zhu K; Deng JB; Shi YY
Sheng Li Xue Bao; 2010 Aug; 62(4):333-8. PubMed ID: 20717634
[TBL] [Abstract][Full Text] [Related]
13. The formation of migrasomes is initiated by the assembly of sphingomyelin synthase 2 foci at the leading edge of migrating cells.
Liang H; Ma X; Zhang Y; Liu Y; Liu N; Zhang W; Chen J; Liu B; Du W; Liu X; Yu L
Nat Cell Biol; 2023 Aug; 25(8):1173-1184. PubMed ID: 37488437
[TBL] [Abstract][Full Text] [Related]
14. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation.
Hailemariam TK; Huan C; Liu J; Li Z; Roman C; Kalbfeisch M; Bui HH; Peake DA; Kuo MS; Cao G; Wadgaonkar R; Jiang XC
Arterioscler Thromb Vasc Biol; 2008 Aug; 28(8):1519-26. PubMed ID: 18566297
[TBL] [Abstract][Full Text] [Related]
15. Carboxyl-terminal Tail-mediated Homodimerizations of Sphingomyelin Synthases Are Responsible for Efficient Export from the Endoplasmic Reticulum.
Hayashi Y; Nemoto-Sasaki Y; Matsumoto N; Tanikawa T; Oka S; Tanaka Y; Arai S; Wada I; Sugiura T; Yamashita A
J Biol Chem; 2017 Jan; 292(3):1122-1141. PubMed ID: 27927984
[TBL] [Abstract][Full Text] [Related]
16. A selective sphingomyelin synthase 2 inhibitor ameliorates diet induced insulin resistance
Huang Y; Huang T; Zhen X; Li Y; Mo M; Ye D; Cheng N
Pharmazie; 2019 Sep; 74(9):553-558. PubMed ID: 31484596
[TBL] [Abstract][Full Text] [Related]
17. Sphingomyelin synthase SMS2 displays dual activity as ceramide phosphoethanolamine synthase.
Ternes P; Brouwers JF; van den Dikkenberg J; Holthuis JC
J Lipid Res; 2009 Nov; 50(11):2270-7. PubMed ID: 19454763
[TBL] [Abstract][Full Text] [Related]
18. Sphingomyelin synthase activity affects TRIF-dependent signaling of Toll-like receptor 4 in cells stimulated with lipopolysaccharide.
Prymas K; Świątkowska A; Traczyk G; Ziemlińska E; Dziewulska A; Ciesielska A; Kwiatkowska K
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Feb; 1865(2):158549. PubMed ID: 31678513
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
Adachi R; Ogawa K; Matsumoto SI; Satou T; Tanaka Y; Sakamoto J; Nakahata T; Okamoto R; Kamaura M; Kawamoto T
Eur J Med Chem; 2017 Aug; 136():283-293. PubMed ID: 28505533
[TBL] [Abstract][Full Text] [Related]
20. Epidermal permeability barrier function and sphingolipid content in the skin of sphingomyelin synthase 2 deficient mice.
Nomoto K; Itaya Y; Watanabe K; Yamashita T; Okazaki T; Tokudome Y
Exp Dermatol; 2018 Aug; 27(8):827-832. PubMed ID: 29345004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
